Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors
作者:Laurie B. Schenkel、Xin Huang、Alan Cheng、Holly L. Deak、Elizabeth Doherty、Renee Emkey、Yan Gu、Hakan Gunaydin、Joseph L. Kim、Josie Lee、Robert Loberg、Philip Olivieri、Jeanne Pistillo、Jin Tang、Qian Wan、Hui-Ling Wang、Shen-Wu Wang、Mary C. Wells、Bin Wu、Violeta Yu、Liqin Liu、Stephanie Geuns-Meyer
DOI:10.1021/jm200911r
日期:2011.12.22
Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative disorders (MPD). Here, we describe the discovery of a thienopyridine series of Jak2 inhibitors that culminates with compounds showing 100- to >500-fold selectivity over the related Jak family kinases in enzyme assays. Selectivity for Jak2 was also observed in TEL-Jak cellular assays, as well as in cytokine-stimulated peripheral blood mononuclear cell (PBMC) and whole blood assays. X-ray cocrystal structures of 8 and 19 bound to the Jak2 kinase domain aided structure activity relationship efforts and, along with a previously reported small molecule X-ray cocrystal structure of the Jak1 kinase domain, provided structural rationale for the observed high levels of Jak2 selectivity.